期刊文献+

通心络胶囊联合瑞舒伐他汀钙治疗冠心病心绞痛的临床效果及对血清ET-1、NO、cTnI、vWF水平的影响 被引量:9

Clinical effect of Tongxinluo capsule combined with rosuvastatin calcium in the treatment of coronary heart disease and angina pectoris and its influences on serum ET-1,NO,cTnI and vWF levels
下载PDF
导出
摘要 目的探讨通心络胶囊联合瑞舒伐他汀钙治疗冠心病心绞痛的临床效果及对血清ET-1、NO、cTnI、vWF水平的影响。方法回顾性选取本院2018年1月至2020年1月收治的100例冠心病心绞痛患者,依据治疗方法将其分为联合治疗组(50例,瑞舒伐他汀钙联合通心络胶囊治疗)和单独治疗组(50例,瑞舒伐他汀钙单独治疗)。比较两组的治疗效果、血清ET-1、NO、cTnI、vWF水平及不良反应发生情况。结果联合治疗组的治疗总有效率为92.0%,明显高于单独治疗组的76.0%(P<0.05)。治疗后,两组的血清ET-1、cTnI、vWF水平均降低,血清NO水平均升高,且联合治疗组明显优于单独治疗组(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论通心络胶囊联合瑞舒伐他汀钙治疗冠心病心绞痛的临床效果显著,能够降低患者的血清ET-1、cTnI、vWF水平,提升血清NO水平,且不会增加不良反应,值得临床推广和应用。 Objective To investigate the clinical effect of Tongxinluo capsule combined with rosuvastatin calcium in the treatment of coronary heart disease and angina pectoris and its influences on serum ET-1,NO,cTnI and vWF levels.Methods A total of 100 patients with coronary heart disease and angina pectoris admitted in our hospital from January 2018 to January 2020 were selected retrospectively,and the patients were divided into combined treatment group(50 cases,rosuvastatin calcium combined with Tongxinluo capsule treatment)and single treatment group(50 cases,rosuvastatin calcium alone treatment)according to the treatment method.The therapeutic effect,serum ET-1,NO,cTnI,vWF levels and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the combined treatment group was 92.0%,which was significantly higher than 76.0%in the single treatment group(P<0.05).After treatment,the serum ET-1,cTnI and vWF levels in the two groups decreased,and the serum NO level increased,and those in the combined treatment group were significantly better than the single treatment group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Tongxinluo capsule combined with rosuvastatin calcium in the treatment of coronary heart disease and angina pectoris has a significant clinical effect,it can reduce the serum ET-1,cTnI,vWF levels of patients,improve the serum NO level,and will not increase the adverse reactions,which is worthy of clinical promotion and application.
作者 刘洁云 LIU Jieyun(Kaifeng Central Hospital,Kaifeng 475000,China)
机构地区 开封市中心医院
出处 《临床医学研究与实践》 2021年第5期144-146,共3页 Clinical Research and Practice
关键词 冠心病 心绞痛 通心络胶囊 瑞舒伐他汀钙 ET-1 NO coronary heart disease angina pectoris Tongxinluo capsule rosuvastatin calcium ET-1 NO
  • 相关文献

参考文献7

二级参考文献85

共引文献67

同被引文献117

引证文献9

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部